Expression of DNA repair and metabolic genes in response to a flavonoid-rich diet

Simonetta Guarrera[1], Carlotta Sacerdote[2], Laura Fiorini[2], Rosa Marsala[2], Silvia Polidoro[1], Sara Gamberini[1,3], Federica Saletta[1], Christian Malaveille[4], Glenn Talaska[5], Paolo Vineis[1,6] and Giuseppe Matullo[1,3]*

[1]*Institute for Scientific Interchange Foundation, Section of Life Sciences, viale Settimio Severo 65, Torino, Italy*
[2]*Department of Biomedical Sciences and Human Oncology, University of Torino, Torino, Italy*
[3]*Department of Genetics, University of Torino, Torino, Italy*
[4]*International Agency for Research on Cancer, 150 Cours Albert-Thomas,69372 Lyon Cedex 08, France*
[5]*Institute for Environmental Health (ML 056), the University of Cincinnati, Cincinnati, OH 45267, USA*
[6]*Department of Epidemiology and Public Health, Imperial College London, Norfolk Place W2 1PG London, UK*

A diet rich in fruit and vegetables can be effective in the reduction of oxidative stress, through the antioxidant effects of phytochemicals and other mechanisms. Protection against the carcinogenic effects of chemicals may also be exerted by an enhancement of detoxification and DNA damage repair mechanisms. To investigate a putative effect of flavonoids, a class of polyphenols, on the regulation of the gene expression of DNA repair and metabolic genes, a 1-month flavonoid-rich diet was administered to thirty healthy male smokers, nine of whom underwent gene expression analysis. We postulated that tobacco smoke is a powerful source of reactive oxygen species. The expression level of twelve genes (*APEX*, *ERCC1*, *ERCC2*, *ERCC4*, *MGMT*, *OGG1*, *XPA*, *XPC*, *XRCC1*, *XRCC3*, *AHR*, *CYP1A1*) was investigated. We found a significant increase ($P < 0.001$) in flavonoid intake. Urinary phenolic content and anti-mutagenicity did not significantly change after diet, nor was a correlation found between flavonoid intake and urinary phenolic levels or anti-mutagenicity. Phenolic levels showed a significant positive correlation with urinary anti-mutagenicity. *AHR* levels were significantly reduced after the diet ($P = 0.038$), whereas the other genes showed a generalized up regulation, significant for *XRCC3* gene ($P = 0.038$). Also in the context of a generalized up regulation of DNA repair genes, we found a non-significant negative correlation between flavonoid intake and the expression of all the DNA repair genes. Larger studies are needed to clarify the possible effects of flavonoids *in vivo*; our preliminary results could help to better plan new studies on gene expression and diet.

DNA repair: Gene expression: Flavonoids: Dietary intervention trial

It is well established that a diet rich in fruit and vegetables can play a role in preventing cancer as well as other chronic degenerative disorders, such as CVD[1–5].

It is widely accepted and supported by many epidemiological studies that phytochemicals contained in vegetables and fruits, including flavonoids and other types of polyphenolic compounds, show complementary and overlapping mechanisms of action, such as antioxidant effects, stimulation of the immune system, antibacterial and antiviral effects, modulation of hormone and detoxification enzymes metabolism, regulation of gene expression in cell proliferation and apoptosis[6–11]. Nevertheless, the few studies on the DNA repair genes *OGG1* and *ERCC1* reported no changes in gene expression levels *in vivo* after a fruit and vegetable or antioxidant-rich diet[12,13].

Epidemiological studies have suggested a protective role of dietary flavonoids against CHD and possibly cancer[14–17].

In two prospective large cohort studies, a significant inverse association of flavonoid/flavone intake with lung cancer risk was found[18,19], while no clear effect of flavonoid intake and risk of bladder cancer was reported.

Although the effect of flavonoids on gene expression has been little studied in human subjects, some studies suggested a flavonoid-mediated modulation of the expression of the *CYP* family genes, whose products are involved in carcinogen activation and detoxification[20–22]. Exposure to polycyclic aromatic hydrocarbons contained in cigarette smoke causes the induction of the *CYP1A* gene family, regulated by the cytosolic protein aryl hydrocarbon receptor (AHR). Flavonoids can either inhibit or activate human *CYP* depending upon their structures, concentration and experimental conditions[22,23]. An inhibition of *CYP1A1* expression in HepG2 cells by resveratrol was previously reported[20], while two dietary flavonoids

showed different effects on the modulation of *CYP1A1* expression in MCF-7 human breast cancer cells[24].

Tobacco smoking is an important risk factor for several types of human cancer including bladder cancer[25–27]. Several compounds contained in cigarette smoke can damage DNA directly (i.e. polycyclic aromatic hydrocarbons and nitrosamines) or through the generation of reactive oxygen species[28,29]. Oxidants, either present in cigarette smoke and/or formed as a metabolic by-product in the lung and bladder cells of smokers, may trigger oxidative damage to DNA and cellular components, contributing to carcinogenesis. Smoke carcinogens and free radicals generate several different types of DNA damage[30].

Within the framework of a larger randomized controlled trial to test the ability of flavonoids to increase urinary anti-mutagenicity and inhibit the formation of DNA damage in the bladder exfoliated cells in a group of healthy male heavy smokers[31,32], we hypothesize that smokers ingesting dietary phenolics might be partially protected against the harmful effects of tobacco compounds. In a subgroup, we examined whether administration of foods rich in flavonoids modulated some DNA repair and metabolic gene expression.

All the DNA repair genes investigated could be potentially involved in repairing DNA damage due to tobacco smoke compounds, which induce bulky DNA adduct formation, base oxidation and give other base alterations and single and double strand breaks.

DNA repair genes were selected because of: (i) the possible role in repairing oxidative DNA damage (base excision repair genes: *APE1*; *OGG1*; *XRCC1*); (ii) the involvement in repairing other DNA adducts of carcinogens whose reactivity is possibly modulated by the antioxidant activity exerted by the flavonoids (nucleotide excision repair genes: *ERCC1*; *ERCC2*; *ERCC4*; *XPA*; *XPC*; *MGMT*); (iii) the repair of double strand breaks (e.g. *XRCC3* gene), which was also observed after flavonoid treatment in *in vitro* studies[33].

Materials and methods

Subjects

In the overall dietary supplementation study[31,32], ninety healthy heavy smokers of air-cured tobacco were recruited among Italian blood donors. Trial participants were all males, aged 35–70 years, resident in the Torino metropolitan area (northern Italy), healthy on the basis of a medical questionnaire and had normal values for urine and blood parameters (cholesterol, TAG, glycaemia, blood pressure, etc.), as tested in the context of selection for blood donation. All the volunteers gave written informed consent according to ethical standard requirements.

In the context of the randomized controlled trial described earlier, we nested a sub-study on DNA repair and metabolic gene expression among nine subjects (GE subgroup) recruited within the 'flavonoid supplement' group, one of the three arms of the trial (see below).

Study design

Volunteers were randomly assigned to three groups, corresponding to three different diets: (i) normal isoenergetic diet (with an adequate administration of fruit and vegetables; (ii) rich in flavonoids, but not based on supplementation; (iii) based on supplementation of flavonoids in the form of green tea, bilberry juice and soya products. A 2-week diet period proved to be suitable to reveal changes in biomarkers of fruit and vegetable intake[34]. In the present study, the volunteers followed the prescribed diet for 1 month in order to guarantee a complete turnover of the bladder cells used for the DNA adduct analysis.

Within the flavonoid-supplementation group, eighteen subjects, hereafter identified as 'supplement' group, completed the dietary protocols and underwent a detailed analysis of dietary information as extracted from diaries. For nine subjects out of the eighteen, blood samples were collected according to proper protocols for RNA extraction, and underwent gene expression analysis ('GE subgroup').

Methods

Flavonoid-rich foods were chosen by an expert dietitian. A recipe booklet was given to each participant as a reference and a professional chef taught all the participants how to prepare recipes with the selected foods in order to limit differences in cooking methods and food choice, making the dietary regimen comparable within each group. For each subject, a trained interviewer recorded dietary and smoking habits by a direct interview at enrolment and after 1 month of the diet. Adherence to dietary protocols was assessed through telephone interviews by using 24-h dietary recalls (every 2 d) as well as weekly domestic visits by a dietitian throughout the 4 week intervention.

Average intakes of flavonoids and some micronutrients (vitamins B_1, B_2, B_3, B_{12}, C, A, D, E, folates, Se) were estimated on the basis of daily dietary records.

Urine was collected weekly, as reported in Malaveille *et al.*[32] Briefly, urine samples were collected in polyethylene bottles on Friday between 16.00 and 22.00 hours, kept at 4°C in the volunteers' homes and collected weekly by a dietitian. Exfoliated bladder cells were immediately filtered from a part of each sample, while the remaining urine was kept at −30°C and analysed within 6 months for anti-mutagenicity and chemical content (phenolics, etc).

The amount of total urinary phenolics was measured in a dimethyl sulphoxide (DMSO) solution of urinary extracts. The glucuronides and sulfates contained in a 24 h urine aliquot containing 3 mg creatinine were enzymatically deconjugated and the amount of phenolics was measured by spectrophotometric analysis[35].

Urine anti-mutagenicity was measured as a decrease in *Salmonella* Typhimurium revertants/total volume of collected urine equivalent as described in Malaveille *et al.*[32].

DNA damage in exfoliated bladder cells was measured as relative adduct labelling $\times 10^{-9}$ by ^{32}P post labelling technique[36] at three time points: baseline; week 2; week 4 of diet.

Blood collection for RNA extraction was done twice (baseline, week 4). Peripheral blood (2 ml) was directly collected in PAXgene Blood RNA Tubes (PreAnalitiX/QIAGEN, Valencia, CA, USA) and total RNA was isolated using a column affinity procedure (PAXgene Blood RNA Kit; QIAGEN) according to the manufacturer's instructions. A DNA nuclease treatment step was included to prevent genomic DNA carry-over. The random primed reverse transcription of 1 μg total RNA to single stranded cDNA was achieved by High-Capacity cDNA Archive Kit (Applied Biosystems, Foster

City, CA, USA) according to the manufacturer's instructions, adding 1 U/μl final concentration of RNAse inhibitor (Applied Biosystems).

Primers and probes for the target genes (*APEX*, *ERCC1*, *ERCC2*, *ERCC4*, *MGMT*, *OGG1*, *XPA*, *XPC*, *XRCC1*, *XRCC3*, *AHR*, *CYP1A1*) were purchased as pre-made assays (Assay on Demand) from Applied Biosystems and analyses carried out according to the producer's instructions. As a reference gene, we used β-*actin* AoD (Hs99999903_m1; Applied Biosystems), which in a preliminary validation assay proved to be suitable for the relative quantitation of mRNA in our samples. Real time PCR analyses were carried out on an ABI Prism 7000 Sequence Detection System (Applied Biosystems). Three replicates for each sample were analysed and a no-template control for each assay was included in all the amplification plates.

Real-time PCR data were collected and analysed by the ABI Prism 7000 SDS Software (Applied Biosystems). A relative quantitation analysis (ΔΔCt method) was performed as described[37].

Statistical analysis

Differences in the levels of all the variables analysed before and after diet (considering week 2 and 4 whenever possible) were tested by parametric (*t* test) and non-parametric methods for paired samples (Wilcoxon and Friedman for two or more groups, respectively). Correlations between variables were tested by Pearson correlation test. All the analyses were performed by the SPSS 13·0 package for personal computers (SPSS Inc., Chicago, IL, USA) and values of $P \leq 0.05$ were considered statistically significant.

Results

The mean age of the subjects was: supplement group 52 (SD 5) years (range 43–63 years); GE subgroup 51 (SD 7) years (range 43–63 years).

The diet-related variation in flavonoid intake (μg) as measured at three different time points (baseline, week 2 and week 4) significantly changed as a consequence of the diet ($P < 0.001$) as shown in Table 1, in agreement with that reported for the overall trial[32].

Urinary phenolic content and anti-mutagenicity as evaluated at the same three time points did not change during the diet period (Table 1).

The whole group and the GE group showed virtually no difference; thus, results are reported in Table 1 for the whole group.

Flavonoid intake during the diet period showed no correlation with either urinary phenolic levels or urinary anti-mutagenicity.

Urinary anti-mutagenicity showed a significant positive correlation with urinary phenolics during the diet period both in the 'supplement' (*n* 18, week 0: Pearson correlation coefficient (PCC) 0·743, $P < 0.001$; week 2: PCC 0·745, $P < 0.001$; week 4: PCC 0·724, $P = 0.001$) and GE subgroup (*n* 9, week 0: PCC 0·607, $P = 0.083$; week 2: PCC 0·774, $P = 0.014$; week 4: PCC 0·760, $P = 0.017$).

No significant difference was found in the mean number/d of cigarettes smoked pre- (baseline) and post-diet both in the overall supplement group (*n* 18; baseline: 21·44 (SD 7·04); week 4: 20·50 (SD 5·85); NS) and in the GE subgroup (*n* 9; baseline: 20·44 (SD 4·42); week 4: 20·33 (SD 3·08); NS).

During the diet period, a negative correlation between smoking and urine anti-mutagenicity was shown for the whole group, statistically significant when considering the GE subgroup (PCC -0.693, $P = 0.038$).

No difference in the mean levels of DNA adducts in exfoliated bladder cells was found during the diet period both in the overall (*n* 18; baseline: 26·8 (SD 22·2) $\times 10^{-9}$; week 2: 27·8 (SD 50·3) $\times 10^{-9}$; week 4: 25·7 (SD 21·2) $\times 10^{-9}$; NS) and in the GE group (*n* 9; baseline: 22·0 (SD 23·9) $\times 10^{-9}$; week 2: 55·4 (SD 78·4) $\times 10^{-9}$; week 4: 21·9 (SD 29·7) $\times 10^{-9}$; NS), as computed by both Friedman test and Wilcoxon paired test.

Gene expression analysis

Considering the GE subgroup (*n* 9), the mean ratio of gene expression level for each of the twelve target genes (pre- *v.* post-diet) ranged from a 0·813-fold mean variation for *AHR* gene to 1·71-fold mean variation for *XPA* (β-*actin* 1; *APEX* 1·187; *ERCC1* 1·113; *ERCC2* 1·132; *ERCC4* 1·014; *MGMT* 1·316; *OGG1* 1·095; *XPA* 1·711; *XPC* 0·971; *XRCC1* 1·125; *XRCC3* 1·271; *AHR* 0·813; *CYP1A1* 1·181).

Table 1. Diet-related variation in flavonoid intake, urinary phenolics and urinary anti-mutagenicity at different time points¶

(Values are means and standard deviations)

	Supplement group (*n* 18)					
	Week 0		Week 2		Week 4	
	Mean	SD	Mean	SD	Mean	SD
Flavonoid intake†	52·47	65·02	236·20	79·48	228·19***	91·86
Urinary phenolics ($\times 10^{-3}$)‡	36·40	16·76	32·80	20·99	33·45	20·61
Urinary anti-mutagenicity ($\times 10^{-4}$)§	345·05	122·71	327·51	132·72	300·80	126·12

Significant diet related variation (Friedman test): ***$P < 0.001$.
† Estimated from dietary recordings.
‡ μg/total volume of collected urine equivalent, as described in Malaveille *et al.*[32]
§ Decrease in revertants/total volume of collected urine equivalent (creatinine corrected), as described in Malaveille *et al.*[32]
¶ For details of subjects and procedures, see Materials and methods.

The majority of the genes seem to undergo a generalized up regulation after the diet period, statistically significant for *XRCC3* gene ($P=0.038$ Wilcoxon paired test; $P=0.036$ paired *t* test), *AHR* gene ($P=0.038$ Wilcoxon paired test; $P=0.026$ paired *t* test) and with borderline significance for *MGMT* gene ($P=0.051$ Wilcoxon paired test; $P=0.107$ paired *t* test).

A positive correlation (Pearson correlation test) between smoking and gene expression levels during the month of diet, statistically significant for *ERCC1* ($P=0.037$) and *ERCC2* ($P=0.045$), is shown for all the genes except *CYP1A1*, which shows a negative though not significant correlation with smoking.

We measured the correlation between the variation of expression levels for the twelve genes at the end of the diet period, which all positively correlate (most of them significantly), except the *CYP1A1* gene, which shows a negative correlation (although not significant) with all the other genes (see supplementary table, available online).

Food and gene expression. Food consumption at baseline and during the month of diet was recorded and categorized according to nutritional profiles (e.g. cereals, meat, vegetables, fruit, dairy, etc.), specifying as separate categories flavonoid-rich foods (soyabeans and derivatives, onions, red wine, green tea and bilberry juice). Micronutrient consumption (folates, vitamins, minerals) as well as flavonoid intake was estimated from dietary records.

Estimated mean dietary flavonoid intake negatively correlates with variations in expression levels of all the examined genes except *CYP1A1* (correlation statistically significant for *ERCC2*, $P=0.049$). Total folates and vitamin B12 levels positively correlate with *CYP1A1* gene expression variations ($P=0.006$ and $P=0.009$ respectively).

Comparing the food intake at baseline and the mean food intake during the diet period (Wilcoxon paired test), we found a significant diet-related change for some food categories both in the overall supplement group and in the GE subgroup as presented in Table 2. However, no statistical significance was found after Bonferroni correction for multiple comparisons.

According to the present results, some food categories seem to affect gene expression levels in the GE subgroup, shown in Table 3. A non-significant positive correlation between citrus fruits, cruciferous vegetables, red wine and fish intakes and the expression levels of the majority of the genes examined was found, while fruits and vegetables showed a generalized non-significant negative correlation ($P>0.05$). Flavonoid-rich foods, such as soya products, onions, green tea and bilberry juice, negatively correlate with the expression of all the genes, except *CYP1A1* (with soya, onions and green tea) and *AHR* (with bilberry juice) ($P>0.05$).

To investigate a short-term effect of specific food consumption on gene expression, we compared in the GE subgroup the food intake the day before baseline blood sampling (baseline

Table 2. Dietary variations during the trial for selected food categories§

(Values are means and standard deviations)

| Food category | Supplement group (*n* 18) | | | | GE group (*n* 9) | | | |
| | BI* | | MDI† | | BI* | | MDI† | |
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Alcohol (ml/d)	87.611	150.915	63.125	95.413	95.778	124.874	71.631	95.792
Bilberry juice (ml/d)	0.000	0.000	29.806‡‡‡	17.694	0.000	0.000	36.099‡‡	19.008
Black tea (ml/d)	0.000	0.000	5.952‡	11.893	0.000	0.000	3.571	5.357
Butter (g/d)	1.389	3.648	1.714	1.502	1.556	4.667	1.317	0.889
Cereals (g/d)	387.000	233.361	396.065	121.500	411.222	232.581	435.218	120.285
Cheese (g/d)	64.889	74.007	37.514	18.400	53.778	54.037	32.266	15.341
Citrus fruit (g/d)	213.611	400.137	146.111	141.790	200.556	309.099	135.405	105.996
Coffee (ml/d)	151.500	62.529	138.635	60.886	169.667	52.593	137.548‡	57.424
Cruciferous vegetables (g/d)	7.722	30.824	38.804‡‡	23.357	14.556	43.667	46.925	21.210
Eggs (g/d)	21.944	50.763	9.119	6.122	28.889	57.813	8.393	6.575
Fish (g/d)	62.000	98.894	46.899	21.592	67.000	101.288	51.849	19.121
Fruit (except citrus fruit) (g/d)	89.222	118.649	218.599‡‡	146.293	93.111	134.363	243.972‡	131.061
Green tea (ml/d)	0.000	0.000	101.607‡‡	218.090	0.000	0.000	76.032‡	74.132
Legumes (g/d)	13.389	56.307	34.960‡‡	20.108	0.222	0.667	40.679‡‡	23.329
Meat (g/d)	92.444	123.068	131.980	60.873	114.889	154.637	136.171	73.267
Milk (ml/d)	70.889	116.004	83.224	69.670	100.222	150.875	96.960	87.856
Olive oil (ml/d)	9.611	10.393	18.190‡‡	11.095	10.222	12.726	19.500	7.420
Onions (g/d)	8.389	15.557	11.970	10.760	12.556	18.676	12.540	5.221
Potatoes (g/d)	28.722	66.486	43.764	20.190	43.556	91.989	40.726	16.055
Red wine (g/d)	177.778	265.905	160.860	155.896	228.556	334.947	172.250	166.635
Seed oil (ml/d)	1.778	7.059	0.798	1.276	3.556	9.939	1.052	1.682
Soya products (g/d)	0.944	4.007	6.516‡	10.986	1.889	5.667	10.571	14.115
Sweets and cakes (g/d)	88.722	68.601	57.796	31.164	116.222	83.195	57.405	27.898
Vegetables (g/d)	175.444	149.448	219.050	125.371	177.222	163.139	213.802	52.881
Water (ml/d)	815.278	494.911	819.444	378.042	700.000	558.458	853.373	440.077

* Baseline intake; food intake the day before the first day of diet.
† Mean dietary intake: food intake abstracted from self-administered daily diaries and averaged over 1 month.
 Significant dietary variation (Wilcoxon Z test): ‡$P \leq 0.05$; ‡‡$P \leq 0.01$; ‡‡‡$P \leq 0.001$ – not significant after Bonferroni correction for multiple test.
§ For details of subjects and procedures, see Materials and methods.

Table 3. Gene expression variations *v.* food intake variation§

Gene expression variation†	APEX 1·187	ERCC1 1·113	ERCC2 1·132	ERCC4 1·014	MGMT 1·316	OGG1 1·095	XPA 1·711	XPC 0·971	XRCC1 1·125	XRCC3 1·271‡	AHR 0·813‡	CYP 1·181
Food category												
Water (ml/d)	−0·527	−0·555	−0·420	0·287	−0·489	−0·498	−0·480	0·128	−0·582	−0·560	−0·007	0·048
Citrus fruit (g/d)	0·116	0·379	0·343	0·486	0·245	0·263	−0·283	0·461	0·202	0·109	−0·161	0·317
Alcohol (ml/d)	0·314	0·339	0·441	−0·210	0·278	0·306	0·285	0·118	0·495	0·427	0·076	−0·820**
Butter (g/d)	0·013	−0·087	−0·077	−0·092	0·011	−0·073	0·138	0·046	0·352	0·128	−0·052	−0·504
Coffee (ml/d)	−0·242	−0·014	0·167	0·014	−0·090	0·004	−0·106	0·198	−0·062	−0·125	−0·437	0·603
Meat (g/d)	0·021	−0·079	−0·211	−0·614	−0·047	−0·090	0·104	−0·545	0·094	−0·015	−0·309	0·187
Cereals (g/d)	−0·462	−0·497	−0·474	0·163	−0·349	−0·471	−0·215	−0·210	−0·555	−0·422	0·095	0·594
Onions (g/d)	−0·487	−0·468	−0·340	−0·164	−0·347	−0·479	−0·405	−0·281	−0·518	−0·464	−0·098	0·419
Cruciferous vegetables(g/d)	0·107	0·041	0·153	−0·330	0·082	0·222	0·202	0·242	0·214	0·018	−0·349	0·301
Sweets and cakes (g/d)	0·526	0·592	0·728*	−0·250	0·537	0·671*	0·537	0·341	0·583	0·556	0·004	−0·085
Cheese (g/d)	−0·572	−0·576	−0·575	0·293	−0·516	−0·562	−0·138	−0·139	−0·395	−0·396	−0·129	0·274
Fruit (except citrus fruit) (g/d)	−0·551	−0·510	−0·599	0·420	−0·453	−0·530	−0·510	0·013	−0·421	−0·547	−0·304	0·665
Milk (ml/d)	0·463	0·278	0·317	−0·449	0·417	0·454	0·631	0·131	0·551	0·420	0·037	−0·019
Legumes (g/d)	−0·071	−0·037	−0·038	−0·467	0·018	−0·036	0·008	−0·256	0·125	−0·043	−0·440	0·564
Bilberry juice (ml/d)	−0·132	−0·326	−0·322	−0·042	−0·269	−0·264	−0·228	−0·048	−0·273	−0·283	0·135	−0·502
Olive oil (ml/d)	0·066	−0·081	−0·273	0·194	0·160	−0·027	0·423	−0·153	0·077	0·141	0·309	0·705*
Seeds oil (ml/d)	0·676*	0·846**	0·780*	0·323	0·619	0·719*	0·388	0·315	0·513	0·714*	0·442	−0·578
Potatoes (g/d)	0·606	0·711*	0·703*	0·141	0·516	0·620	0·394	0·277	0·552	0·664	0·351	−0·851**
Fish (g/d)	0·272	0·214	0·306	−0·020	0·304	0·233	0·072	0·105	−0·027	0·174	0·524	−0·206
Soya products (g/d)	−0·559	−0·655	−0·518	−0·387	−0·523	−0·500	−0·396	−0·132	−0·453	−0·664	−0·576	0·632
Black tea (ml/d)	−0·051	−0·148	−0·183	−0·004	−0·101	−0·035	0·003	−0·057	−0·359	−0·222	0·072	0·559
Green tea (ml/d)	−0·251	−0·215	−0·059	−0·413	−0·282	−0·145	−0·500	−0·011	−0·357	−0·466	−0·510	0·283
Eggs (g/d)	−0·576	−0·495	−0·378	−0·043	−0·624	−0·530	−0·338	−0·181	−0·353	−0·427	−0·422	−0·357
Vegetables (g/d)	−0·523	−0·475	−0·442	0·178	−0·451	−0·462	−0·178	−0·216	−0·559	−0·424	−0·094	0·571
Red wine (g/d)	0·147	0·155	0·324	−0·486	0·164	0·291	0·230	0·131	0·225	0·104	−0·334	0·303

Pearson Correlation Coefficient: *$P \leq 0.05$; **$P \leq 0.01$.

† Gene expression variation values are reported for quick reference: 1·000, no variation in gene expression after the diet; >1·000, up regulation of gene expression after the diet; <1·000, down regulation of gene expression after the diet.

Significant gene expression variations (Wilcoxon test) ‡$P < 0.05$ − not significant after Bonferroni correction for multiple tests.

§ For details of subjects and procedures, see Materials and methods.

pre sampling) and the food intake the day before blood sampling after 4 weeks of diet (week 4 pre-sampling; 4-PS). The variation in mean fruit consumption proved to be statistically significant (baseline pre-sampling 93·11 (SD 134·36) g/d *v.* 4-PS 347·00 (SD 230·44) g/d, $P = 0.012$), while mean green tea and vegetable intakes were increased, but not significantly (baseline pre-sampling 0·00 ml/d *v.* 4-PS 50·00 (SD 75·00) ml/d, $P = 0.083$ and baseline pre-sampling 177·22 (SD 163·14) g/d *v.* 4-PS 230·44 (SD 113·61) g/d, $P = 0.066$, respectively).

Considering food categories, a negative correlation between gene expression variations and cheese intake was found for all the genes, statistically significant for *ERCC1* ($P = 0.021$), *ERCC2* ($P = 0.033$), *MGMT* ($P = 0.028$) and *OGG1* ($P = 0.029$). Seed oil intake also negatively correlated with gene expression variations in all the genes, significantly for *ERCC1* ($P = 0.011$), *ERCC2* ($P = 0.024$) and *OGG1* ($P = 0.046$), while showing a positive though not significant correlation with *CYP1A1* gene expression variations.

CYP1A1 expression positively correlated with coffee intake ($P = 0.037$), while negatively correlating with alcohol intake ($P = 0.047$).

Flavonoid intake on 4-PSd negatively correlated with variations in expression levels of all the examined genes and the correlation was statistically significant for *ERCC2* ($P = 0.049$).

Discussion

In the context of a randomized dietary intervention trial to assess the ability of flavonoids to increase urinary anti-mutagenicity and inhibit DNA damage in male heavy smokers, we conducted a pilot study aiming at investigating a possible effect of a flavonoid-rich diet on the expression levels of twelve genes: ten DNA repair genes belonging to different repair pathways (nucleotide excision repair, base excision repair, double strand breaks repair) and two metabolic genes (*CYP1A1* and *AHR*). Flavonoids can be hypothesized to modulate the expression levels of the afore-mentioned genes according to two distinct mechanisms: (i) a down regulation of DNA repair genes could be expected if the antioxidant properties of flavonoids contribute to reduce the burden of reactive oxygen species that can damage DNA; or (ii) a modulation (up regulation or down regulation) of the expression levels could be expected if the diet-derived flavonoids exert a direct effect on gene expression.

The trial demonstrated the expected modification in diet-related flavonoid intake as assessed from dietary diaries, achieved through dedicated instructions given to volunteers by a chef. Although some authors describe urinary excretion of dietary-derived polyphenols and flavonoid aglycones or flavonoid conjugated in human subjects as biomarkers of dietary intake[38,39], the present data do not support a substantial change in urinary phenolics as a consequence of the trial.

Factors influencing bioavailability include the chemical properties of the polyphenols, deconjugation/reconjugation in the intestines, intestinal absorption and enzymes available for metabolism[40].

Nevertheless, the strong correlation between urinary phenolic levels, not affected by dietary changes, and urine anti-mutagenicity against 2-amino-1-methyl-6-phenylimidazo [4,5-6]pyridine (PhIP)-induced mutations *in vitro*, which was shown and discussed previously[32], supports a protective role

of polyphenols and/or their bacterial metabolites against mutagens, such as heterocyclic amines, contained in tobacco smoke.

Although several studies report a beneficial effect of flavonoids against chronic degenerative diseases and a protective role against cancer through their antioxidant properties, some authors describe a detrimental effect of some dietary bioflavonoids, which were shown to cause a high rate of DNA breaks in the *MML* gene, whose translocations are involved in the onset of infant leukaemia[33]. Interestingly, in our sample of subjects the gene *XRCC3* belonging to the double strand break repair pathway is significantly up regulated. XRCC3 participates in DNA double-strand break and cross-link repair through homologous recombination and contributes, as other RAD51-related proteins, to the maintenance of chromosomal stability[41–43].

A high frequency of chromosomal instability or aberrations induced by tobacco-related carcinogens in bladder cancer is to be expected. Indeed, a number of studies showed aberrations and allelic losses in different chromosomes[44,45], so bladder cancer can be considered one of the cancers prone to chromosomal instability. In this context, also, certain flavonoids could apparently produce similar damage, inducing in particular double strand breaks repair through the homologous recombination pathway.

Even though *AHR* expression seems to be significantly reduced in our sample after the diet period, we found an increase in the expression levels of *CYP1A1*, whose induction is known to be mediated by polycyclic aromatic hydrocarbon activated AHR.

It was shown that lack of AHR-mediated induction of *CYP1A1* conferred protection against benzo[a]pyrene (B[a]P) induced carcinogenesis in *AHR* knock-out mice[46,47], and that a resveratrol-mediated inhibition of *CYP1A1* and *CYP1B1* expression can reduce the B[a]P adduct formation in human bronchial epithelial cells[48].

Given this, an up regulation of *CYP1A1* can be supposed to be detrimental. Nevertheless, a flavonoid mediated stimulation/induction of *CYP* family genes can activate cellular defence mechanisms, allowing a more effective response to future stressors, according to the principles of hormesis[49,50]. It is accepted today that flavonoids can exert their protective effect through a stressor mechanism, predisposing the cells to better respond to damaging agents. Depending on doses and chemical properties, some flavonoids can show both anti-oxidant and pro-oxidant activity[51]. Quercetin, a flavonoid contained in high doses in onions, can be activated to DNA reactive species, with the formation of alkylating DNA-reactive intermediates and proved to be mutagenetic, at least *in vitro*, through several mechanisms reviewed in Rietjens *et al.*[52]. An *in vitro* AHR mediated induction of *CYP1A1* stimulated by quercetin, was also described[24]. In the present sample, no relationship was found between onion intake and gene expression, suggesting that dietary intakes of onion-derived quercetin may not be enough to elicit a detectable induction of *CYP* family. Moreover, adduct levels did not significantly change after the diet, indicating no detrimental effect of onion intake on quercetin-induced AHR-mediated carcinogenesis in human subjects, at least in dietary amounts.

However, a possible limitation of the DNA adducts analysis in the present study should be taken into account. Even though

exfoliated bladder cells proved to be suitable for biomarker analysis[53–58] and the DNA adduct detection in exfoliated bladder cells by ^{32}P post-labelling is a commonly used analysis whose feasibility is well proven[59–63], we found no change in exfoliated bladder cell DNA adduct levels after the diet. In addition to advocating no effect of dietary flavonoid intake on the DNA adduction state, this may also be explained considering that exfoliated cells obtained in a urine sample are terminally differentiated and as such likely have much lower metabolic activity than the stem cells from which they arose, so DNA damage is less likely to be repaired.

Even in the context of a generalized up regulation of DNA repair genes, we found an inverse correlation between flavonoid intake and gene expression levels, which may suggest a flavonoid-mediated reduction of smoke-induced DNA damage, that should nevertheless be confirmed in larger studies. Although the present findings are intriguing, it must be remembered that this is a pilot study on a small number of subjects and with a limited power: even if the inter-variability among subjects concerning gene expression levels can be in part corrected by the choice of a relative quantitation assay using a housekeeping gene as an internal reference as described in the Methods section, increasing the number of subjects can overwhelm the occurrence of random variability due to uncontrollable factors (e.g. the subjects do not share exactly the same environment).

Moreover, it would be reductive to ascribe to flavonoids a single protective mechanism. A synergistic effect of several compounds and mechanisms of action resulting in a cumulative beneficial effect against carcinogenesis seems to be a more realistic interpretation. For instance, antioxidant properties of flavonoids are effective in scavenging free radicals, thus reducing oxidative DNA damage and initiation of lipid peroxidation, which also leads to the formation of DNA-damaging reactive species[64–66]. In addition to having antioxidant properties, polyphenolic compounds, including flavonoids, were found to inhibit the formation of N-nitroso compounds (e.g. from nitrosamine in tobacco products, drugs, nitrite-cured meat), which are a known aetiological factor for tumours in stomach, oesophagus, nasopharynx, urinary bladder and colon[67,68]. Several other mechanisms of action of subclasses of flavonoids are reported and reviewed in Mariappan et al.[69], including modulation of gene expression of several genes involved in cellular processes (proliferation, signalling, immune response transcriptional regulation, apoptosis, etc.) and anti-proliferative properties by induction of apoptosis and inhibition of nuclear transcription factors and signal transduction pathways[70–73].

Despite the growing bulk of literature about flavonoids as putative anti-cancer compounds, the results are often contrasting and much remains to be clarified about the effects of specific categories of flavonoids on human health and the underlying biological processes. The contribution of each single mechanism of action of a specific flavonoid or subclass is far from being completely characterized, and synergisms and cumulative effect should be taken into account. An extension of the present study to a larger sample under more controlled dietary conditions is warranted, including functional tests (e.g. Comet Assay; Host Cell Reactivation Assay) to better understand the impact of a flavonoid/polyphenol-rich diet on DNA repair pathways.

Note

Supplementary information accompanies this paper on the Journal's website (http://journals.cambridge.org).

References

1. Kris-Etherton PM, Hecker KD, Bonanome A, Coval SM, Binkoski AE, Hilpert KF, Griel AE & Etherton TD (2002) Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. *Am J Med* **113**, Suppl 9B, 71S–88S.
2. Lock K, Pomerleau J, Causer L, Altmann DR & McKee M (2005) The global burden of disease attributable to low consumption of fruit and vegetables: implications for the global strategy on diet. *Bull World Health Organ* **83**, 100–108.
3. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M & Comparative Risk Assessment collaborating group (Cancers) (2005) Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. *Lancet* **366**, 1784–1793.
4. He FJ, Nowson CA & MacGregor GA (2006) Fruit and vegetable consumption and stroke: meta-analysis of cohort studies. *Lancet* **367**, 320–326.
5. Pomerleau J, Lock K & McKee M (2006) The burden of cardiovascular disease and cancer attributable to low fruit and vegetable intake in the European Union: differences between old and new Member States. *Public Health Nutr* **9**, 575–583.
6. Dragsted LO, Strube M & Larsen JC (1993) Cancer-protective factors in fruits and vegetables: biochemical and biological background. *Pharmacol Toxicol* **72**, 116–135.
7. Formica JV & Regelson W (1995) Review of the biology of quercetin and related bioflavonoids. *Food Chem Toxicol* **33**, 1061–1080.
8. Waladkhani AR & Clemens MR (1998) Effect of dietary phytochemicals on cancer development. *Int J Mol Med* **1**, 747–753.
9. Bub A, Watzl B, Blockhaus M, Briviba K, Liegibel U, Muller H, Pool-Zobel BL & Rechkemmer G (2003) Fruit juice consumption modulates antioxidative status, immune status and DNA damage. *J Nutr Biochem* **14**, 90–98.
10. Hakim IA, Harris RB, Brown S, Chow HH, Wiseman S, Agarwal S & Talbot W (2003) Effects of increased tea consumption on oxidative DNA damage among smokers: a randomized controlled study. *J Nutr* **133**, 3303S–3309S.
11. Karou D, Dicko MH, Simpore J & Traore AS (2005) Antioxidant and antibacterial activities of polyphenols from ethnomedicinal plants of Burkina Faso. *Afr J Biotechnol* **4**, 823–828.
12. Collins AR, Harrington V, Drew J & Melvin R (2003) Nutritional modulation of DNA repair in a human intervention study. *Carcinogenesis* **24**, 511–515.
13. Moller P, Vogel U, Pedersen A, Dragsted LO, Sandstrom B & Loft S (2003) No effect of 600 grams fruit and vegetables per

day on oxidative DNA damage and repair in healthy nonsmokers. *Cancer Epidemiol Biomarkers Prev* **12**, 1016–1022.

14. Janssen PLTMK, Mensik RP, Cox FJ, Harryvan JL, Hovenier R, Hollman PC & Katan MB (1998) Effects of the flavonoids quercetin and apigenin on hemostasis in healthy volunteers: results from an in vitro and a dietary supplement study. *Am J Clin Nutr* **67**, 255–262.

15. Ross JA & Kasum CM (2002) Dietary flavonoids: Bioavailability, metabolic effects, and safety. *Ann Rev Nutr* **22**, 19–34.

16. Weisburger JH & Chung FL (2002) Mechanisms of chronic disease causation by nutritional factors and tobacco products and their prevention by tea polyphenols. *Food Chem Toxicol* **40**, 1145–1154.

17. Ren W, Qiao Z, Wang H, Zhu L & Zhang L (2003) Flavonoids: Promising anticancer agents. *Med Res Rev* **23**, 519–534.

18. Knekt P, Jarvinen R, Seppanen R, Hellovaara M, Teppo L, Pukkala E & Aromaa A (1997) Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. *Am J Epidemiol* **146**, 223–230.

19. Hirvonen T, Virtamo J, Korhonen P, Albanes D & Pietinen P (2001) Flavonol and flavone intake and the risk of cancer in male smokers (Finland). *Cancer Causes Control* **12**, 789–796.

20. Ciolino HP & Yeh GC (1999) Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. *Mol Pharmacol* **56**, 760–767.

21. Chao PDL, Hsiu SL & Hou YC (2002) Flavonoids in herbs: biological fates and potential interactions with xenobiotics. *J Food Drug Anal* **10**, 219–228.

22. Murray M (2006) Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis. *Curr Drug Metab* **7**, 67–81.

23. Moon YJ, Wang X & Morris ME (2006) Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism. *Toxicol in Vitro* **20**, 187–210.

24. Ciolino HP, Daschner PJ & Yeh GC (1999) Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially. *Biochem J* **340**, 715–722.

25. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Human Cancer (1986) *Tobacco Smoking*, vol 38. Lyon: IARC Scientific Publications.

26. Zeegers MP, Kellen E, Buntinx F & van den Brandt PA (2004) The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. *World J Urol* **21**, 392–401.

27. Schollnberger H, Manuguerra M, Bijwaard H, Boshuizen H, Altenburg HP, Rispens SM, Brugmans MJ & Vineis P (2006) Analysis of epidemiological cohort data on smoking effects and lung cancer with a multistage cancer model. *Carcinogenesis* **27**, 1432–1444.

28. Nair J, Ohshima H, Nair UJ & Bartsch H (1996) Endogenous formation of nitrosamines and oxidative DNA-damaging agents in tobacco users. *Crit Rev Toxicol* **26**, 149–161.

29. Phillips DH (2002) Smoking-related DNA and protein adducts in human tissues. *Carcinogenesis* **23**, 1979–2004.

30. Godschalk R, Nair J, van Schooten FJ, Risch A, Drings P, Kayser K, Dienemann H & Bartsch H (2002) Comparison of multiple DNA adduct types in tumor adjacent human lung tissue: effect of cigarette smoking. *Carcinogenesis* **23**, 2081–2086.

31. Malaveille C, Hautefeuille A, Pignatelli B, Talaska G, Vineis P & Bartsch H (1998) Antimutagenic dietary phenolics as antigenotoxic substances in urothelium of smokers. *Mutat Res* **402**, 219–224.

32. Malaveille C, Fiorini L, Bianchini M, Davico L, Bertinetti S, Allegro G, Hautefeuille A, Sacerdote C & Vineis P (2004) Randomized controlled trial of dietary intervention: association between level of urinary phenolics and anti-mutagenicity. *Mutat Res* **561**, 83–90.

33. Strick R, Strissel PL, Borgers S, Smith SL & Rowley JD (2000) Dietary bioflavonoids induce cleavage in the *MML* gene and may contribute to infant leukemia. *PNAS* **97**, 4790–4795.

34. Brevik A, Rasmussen SE, Drevon CA & Andersen LF (2004) Urinary excretion of flavonoids reflects even small changes in the dietary intake of fruits and vegetables. *Cancer Epidemiol Biomarkers Prev* **13**, 843–849.

35. Malaveille C, Hautefeuille A, Pignatelli B, Talaska G, Vineis P & Bartsch H (1996) Dietary phenolics as anti-mutagens and inhibitors of tobacco-related DNA adduction in the urothelium of smokers. *Carcinogenesis* **17**, 2193–2200.

36. Talaska G, Schamer M, Skipper P, Tannenbaum S, Caporaso N, Unruh L, Kadlubar FF, Bartsch H, Malaveille C & Vineis P (1991) Detection of carcinogen-DNA adducts in exfoliated urothelial cells of cigarette smokers: association with smoking, hemoglobin adducts, and urinary mutagenicity. *Cancer Epidemiol Biomarkers Prev* **1**, 61–66.

37. Applied Biosystems (2001) *ABI prism 7700 SDS User Bulletin #2*. Foster City, CA: Applied Biosystems.

38. de Vries JHM, Hollman PCH, Meyboom S, Buysman MN, Zock PL, van Staveren WA & Katan MB (1998) Plasma concentrations and urinary excretion of the antioxidant flavonols quercetin and kaempferol as biomarkers for dietary intake. *Am J Clin Nutr* **68**, 60–65.

39. Bourne LC & Rice-Evance C (1999) Detecting and measuring bioavailability of phenolic and flavonoids in humans: pharmacokinetics of urinary excretion of dietary ferulic acid. *Methods Enzymol* **299**, 91–106.

40. Yang CS, Landau JM, Huang MT & Newmark HL (2001) Inhibition of carcinogenesis by dietary polyphenolic compounds. *Annu Rev Nutr* **21**, 381–406.

41. Tebbs RS, Zhao Y, Tucker JD, Scheerer JB, Siciliano MJ, Hwang M, Liu N, Legerski RJ & Thompson LH (1995) Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene. *Proc Natl Acad Sci USA* **92**, 6354–6358.

42. Liu N, Lamerdin JE, Tebbs RS, *et al.* (1998) XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages. *Mol Cell* **1**, 783–793.

43. Brenneman MA, Weiss AE, Nickoloff JA & Chen DJ (2000) XRCC3 is required for efficient repair of chromosome breaks by homologous recombination. *Mutat Res* **459**, 89–97.

44. Czerniak B, Li L, Chaturvedi V, Ro JY, Johnston DA, Hodges S & Benedict WF (2000) Genetic modeling of human urinary bladder carcinogenesis. *Genes Chromosomes Cancer* **27**, 392–402.

45. Hartmann A, Rosner U, Schlake G, Dietmaier W, Zaak D, Hofstaedter F & Knuechel R (2000) Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis. *Lab Invest* **80**, 709–718.

46. Jang M, Cai L, Udeani GO, *et al.* (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. *Science* **275**, 218–220.

47. Dertinger SD, Silverstone AE & Gasiewicz TA (1998) Influence of aromatic hydrocarbon receptor-mediated events on the genotoxicity of cigarette smoke condensate. *Carcinogenesis* **19**, 2037–2042.

48. Berge G, Øvrebø S, Botnen IV, Hewer A, Phillips DH, Haugen A & Mollerup S (2004) Resveratrol inhibits benzo[a]pyrene-DNA adduct formation in human bronchial epithelial cells. *Brit J Cancer* **91**, 333–338.

49. Bukowski JA & Lewis RJ (2000) Hormesis and health: a little of what you fancy may be good for you. *South Med J* **93**, 371–374.

50. Kitchin KT (2002) Defining, explaining and understanding hormesis. *Hum Exp Toxicol* **21**, 105–106, discussion 113–114.

51. Kessler M, Ubeaud G & Jung L (2003) Anti- and pro-oxidant activity of rutin and quercetin derivatives. *J Pharm Pharmacol* **55**, 131–142.

52. Rietjens IM, Boersma MG, van der Woude H, Jeurissen SM, Schutte ME & Alink GM (2005) Flavonoids and alkenylbenzenes: mechanisms of mutagenic action and carcinogenic risk. *Mutat Res* **574**, 124–138.

53. Degtyar P, Neulander E, Zirkin H, Yusim I, Douvdevani A, Mermershtain W, Kaneti J & Manor E (1997) Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder. *Urology* **63**, 398–401.

54. Dörrenhaus A, Müller JI, Golka K, Jedrusik P, Schulze H & Föllmann W (2000) Cultures of exfoliated epithelial cells from different locations of the human urinary tract and the renal tubular system. *Arch Toxicol* **74**, 618–626.

55. Fracasso ME, Franceschetti P, Doria D, Talamini G & Bonetti F (2004) DNA breaks as measured by the alkaline comet assay in exfoliated cells as compared to voided urine cytology in the diagnosis of bladder cancer: a study of 105 subjects. *Mutat Res* **564**, 57–64.

56. Murray EB & Edwards JW (2005) Differential induction of micronuclei in peripheral lymphocytes and exfoliated urothelial cells of workers exposed to 4,4′-methylenebis-(2-chloroaniline) (MOCA) and bitumen fumes. *Rev Environ Health* **20**, 163–176.

57. Bollmann M, Heller H, Bankfalvi A, Griefingholt H & Bollmann R (2005) Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer? *BJU Int* **95**, 1219–1225.

58. Dörrenhaus A, Muller T & Roos PH (2006) Increased CYP1A1 expression in human exfoliated urothelial cells of cigarette smokers compared to non-smokers. *Arch Toxicol* (published online 1 September 2006, doi:10.1007/s00204-006-0134-9).

59. Bartsch H, Castegnaro M, Camus AM, Schouft A, Geneste O, Rojas M & Alexandrov K (1993) Analysis of DNA adducts in smokers' lung and urothelium by ^{32}P-postlabelling: metabolic phenotype dependence and comparisons with other exposure markers. *IARC Sci Publ* **124**, 331–340.

60. Zhou Q, Talaska G, Jaeger M, et al. (1997) Benzidine-DNA adduct levels in human peripheral white blood cells significantly correlate with levels in exfoliated urothelial cells. *Mutat Res* **393**, 199–205.

61. Talaska G, Maier A, Henn S, Booth-Jones A, Tsuneoka Y, Vermeulen R & Schumann BL (2002) Carcinogen biomonitoring in human exposures and laboratory research: validation and application to human occupational exposures. *Toxicol Lett* **134**, 39–49.

62. Vermeulen R, Talaska G, Schumann B, Bos RP, Rothman N & Kromhout H (2002) Urothelial cell DNA adducts in rubber workers. *Environ Mol Mutagen* **39**, 306–313.

63. Talaska G, Al-Zoughool M, Malaveille C, et al. (2006) Randomized controlled trial: effects of diet on DNA damage in heavy smokers. *Mutagenesis* **21**, 179–183.

64. van Acker SA, van den Berg DJ, Tromp MN, Griffioen DH, van Bennekom WP, van der Vijgh WJ & Bast A (1996) Structural aspects of antioxidant activity of flavonoids. *Free Radic Biol Med* **20**, 331–342.

65. Dragsted LO (2003) Antioxidant actions of polyphenols in humans. *Int J Vitam Nutr Res* **73**, 112–119.

66. Sang S, Hou Z, Lambert JD & Yang CS (2005) Redox properties of tea polyphenols and related biological activities. *Antioxid Redox Signal* **7**, 1704–1714.

67. Bartsch H, Pignatelli B, Calmels S & Ohshima H (1993) Inhibition of nitrosation. *Basic Life Sci* **61**, 27–44.

68. Mirvish SS (1995) Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC. *Cancer Lett* **93**, 17–48.

69. Mariappan D, Winkler J, Parthiban V, Doss MX, Hescheler J & Sachinidis A (2006) Dietary small molecules and large-scale gene expression studies: an experimental approach for understanding their beneficial effects on the development of malignant and non-malignant proliferative diseases. *Curr Med Chem* **13**, 1481–1489.

70. Lee LT, Huang YT, Hwang JJ, Lee PPH, Ke FC, Nair MP, Kanadaswami C & Lee MT (2002) Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. *Anticancer Res* **222**, 1615–1627.

71. Fresco P, Borges F, Diniz C & Marques MP (2006) New insights on the anticancer properties of dietary polyphenols. *Med Res Rev* **26**, 747–766.

72. Narayanan BA (2006) Chemopreventive agents alter global gene expression pattern: predicting their mode of action and targets. *Curr Cancer Drug Targets* **6**, 711–727.

73. Rahman I, Biswas SK & Kirkham PA (2006) Regulation of inflammation and redox signaling by dietary polyphenols. *Biochem Pharmacol* **72**, 1439–1452.

Supplementary Table. Pre diet *vs* post diet gene expression correlations.

	APEX	ERCC1	ERCC2	ERCC4	MGMT	OGG1	XPA	XPC	XRCC1	XRCC3	AHR	CYP
APEX	–											
ERCC1	0.911***	–										
ERCC2	0.722*	0.885**	–									
ERCC4	0.151	0.297	0.201	–								
MGMT	0.975***	0.929***	0.759*	0.214	–							
OGG1	0.931***	0.966***	0.896***	0.275	0.934***	–						
XPA	0.865**	0.684*	0.528	− 0.007	0.814**	0.764*	–					
XPC	0.452	0.576	0.701*	0.620	0.518	0.675*	0.293	–				
XRCC1	0.909***	0.901***	0.753*	0.218	0.930***	0.900***	0.803**	0.571	–			
XRCC3	0.784*	0.839**	0.631	0.200	0.790*	0.772*	0.762*	0.296	0.876**	–		
AHR	0.728*	0.533	0.323	0.345	0.682*	0.582	0.753*	0.233	0.511	0.469	–	
CYP	− 0.308	− 0.308	− 0.390	− 0.038	− 0.214	− 0.288	− 0.312	− 0.164	− 0.339	− 0.293	− 0.290	–

Pearson Correlation Coefficients are reported: *$P \leq 0.05$; **$P \leq 0.01$, ***$P \leq 0.001$